v3.26.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Jun. 30, 2026
Dec. 31, 2025
Current assets:    
Cash and cash equivalents $ 18,617,000 $ 11,520,000
Short-term investments 0 1,496,000
Prepaid clinical trial expenses 228,000 201,000
Other prepaid expenses and current assets 575,000 259,000
Assets held for sale 43,000 54,000
Total current assets 19,463,000 13,530,000
Property and equipment, net 36,000 50,000
Other assets 4,000 11,000
Total assets 19,503,000 13,591,000
Current liabilities    
Accounts payable 2,073,000 1,161,000
Accrued clinical trial costs 193,000 1,081,000
Accrued expenses 1,224,000 290,000
Current portion, promissory note 0 1,250,000
Total current liabilities 3,490,000 3,782,000
Long-term liabilities    
Promissory note 9,200,000 8,450,000
Warrant liability 1,300,000 8,000,000
Total liabilities 13,990,000 20,232,000
Commitments and contingencies (Note 8)
Stockholders' equity (deficit)    
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; no shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively 0 0
Common stock, $0.0001 par value; 500,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; 30,736,401 and 15,437,410, issued and outstanding at June 30, 2026 and December 31, 2025, respectively 6,000 4,000
Additional paid-in capital 197,510,000 182,681,000
Accumulated deficit (192,002,000) (189,326,000)
Accumulated other comprehensive loss (1,000) 0
Total stockholders' equity (deficit) 5,513,000 (6,641,000)
Total liabilities and stockholders' equity (deficit) $ 19,503,000 $ 13,591,000